Eli Lilly and Company

Deciphera Pharmaceuticals, LLC

Sheng-Bin Peng

Daniel L Flynn

Michael D Kaufman

Philip Arthur Hipskind

David Matthew Marquis

James Robert Henry

Lakshminarayana Vogeti

Peter Edward Vaillancourt

Liang Zeng Yan

Bryan D Smith

Victor H Obungu

Wayne David Kohn

Scott Wise

Wei-Ping Lu

Cindy Takeuchi Dickerson

David Andrew Coates

Deqi Guo

Timothy Malcolm Caldwell

Serge Louis Boulet

William C Patt

David Anthony Barda

Tim A Smitka

Mohammad Sadegh Zia-Ebrahimi

Matthew David Belvo

Adam Joseph Kreuzman

Chong Si

Palaniappan Kulanthaivel

Kevin Charles Fortner

Ryan James Linder

David Michael Hyman

The present invention provides compounds of the formula: where R, R, R, R, R, A, B, and Y are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and salts for treating patients for cancer.

KRas G12C inhibitors

The present invention provides compounds of the Formula I below where R1, R2 and m are as described herein, pharmaceutically acceptable salts of the compounds of Formula 1, and methods of using these compounds and salts for treating patients for cancer.

This invention provides compounds of Formula I: (Formula I should be inserted here) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula I; and use of a compound of Formula I for treating specified cancers. 

RAF inhibitor compounds

This invention provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I); and use of a compound of Formula (I) for treating specified cancers. 

Raf inhibitor compounds

The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis.

Anti-CXCR4 antibodies

Provided are lactam-cyclized peptide CXCR4 antagonists useful in the treatment of cancers, rheumatoid arthritis, pulmonary fibrosis, and HIV infection.

Cyclic peptide CXCR4 antagonists

Provided are novel lipoglycopeptides exhibiting bacterial signal peptidase inhibitory activity. Also provided are actinomycete strains that produce these lipoglycopeptides, methods of producing such lipoglycopeptides by culturing these strains, pharmaceutical compositions comprising these lipoglycopeptides, and methods of treating bacterial infections comprising contacting bacteria susceptible to treatment with the present bacterial signal peptidase inhibitor lipoglycopeptides. These lipoglycopeptides are useful in human and veterinary medicine.

Lipoglycopeptide antibiotics

Growing community of inventors

Carmel, IN, United States of America

Sheng-Bin Peng